"Companies dependent on consumer spending have been under a cloud on Wall Street," cautions Chuck Carlson, the industry's leading expert on dividend reinvestment plans.

"However, Disney (NYSE: DIS) is one of those consumer-dependent stocks where conventional wisdom may not be correct," he adds in his The DRIP Investor.

"With $4-per-gallon gasoline, one would think that the high cost of travel would take some steam out of the firm's theme park attendance. However, recent results on this front were decent, and the firm's other businesses have held up, too.

"To be sure, a prolonged recession would impact business. Still, Disney has done a nice job of positioning its theme parks as an affordable vacation for families, and that should help it continue to weather
economic weakness.

"Disney surprised Wall Street with the resiliency of its theme-park and resort business in the fiscal second quarter. Revenue for the unit jumped 11% in the quarter. Results were aided by a boost in international visitors taking advantage of the weak dollar.

"Socially Responsible Investing (SRI) is no longer relegated to a tiny corner of the investment landscape; indeed, according to the Social Investment Forum, SRI now accounts for $2.7 trillion, up more than 18% since 2005," says Chuck Carlson.

Here, the editor of The DRIP Investor offers five stock that both rank high for their social responsibility and also stand out based on more traditional earnings and valuation analysis.

"The Social Investment Forum estimates that more than one in every 10 dollars under professional management in the U.S. is involved in SRI investing. What is driving the growth in SRI?

"One factor is the increasing numbers of women and younger investors among the investor populace have fueled demand for SRI investments.

"In addition, we see an increased focus on environment, social, and corporate governance issues. Further, widely publicized stories concerning global warming as well as various corporate governance issues, have caused many investors to reconsider how they deploy their investment capital.

"I've never been a big fan of deep cyclical industries, such as autos, chemicals, and steel; the companies tend to have violent swings in their results as a result of economic cycles," observes Chuck Carlson.

However, says the editor of The DRIP Investor, "Every so often I'm willing to make an exception for a well-run cyclical company. Arcelor Mittal (NYSE: MT) is such a company." Here is his review.

"Arcelor Mittal is the world's number one steel company, with 310,000 employees in more than 60 countries. It has demonstrated the ability to navigate the often-difficult waters of the steel industry.

"For investors who are looking for stocks that should hold up in an inflationary environment, Mittal should be of interest. The company has pricing power -- for example, the company just announced a $100-per-ton price increase on its carbon and high-strength low-alloy plate steel products for all North American orders, effective May 4.

"The stock that I think may put up the best performance in 2008 is Bristol-Myers Squibb (NYSE: BMY)," says Chuck Carlson, the industry's leading authority on dividend reinvestment plans and editor of The DRIP Investor.

Here, the advisor looks at the stock's role in the defensive pharmaceutical sector, its increasing dividend yield, and its takeover potential.

"I know this may strike some of you as an odd choice, especially given the fairly mediocre performance these shares have turned in over the last several years. However, some of the uncertainty hanging over these shares has been lifted.

"The firm has won its patent suit with Apotex over its important Plavix medication. Also, Bristol-Myers has finalized a civil settlement agreement with the U.S. Department of Justice.

"I like that the firm is cutting costs as well restructuring its operations. The company plans to reduce total headcount by approximately 10% by the end of 2010. Bristol-Myers recently announced the sale of its medical-imaging business.

"And Wall Street anticipates additional asset sales, possibly the company's woundcare supplies company, ConvaTec, and its Mead Johnson nutritional business. These moves would be consistent with the company's plan to become more of a player in the BioPharma sector.

"Two additional reasons Bristol- Myers may get some play in 2008 is that 1) health-care stocks traditionally perform well during rocky market periods; and 2) high dividend yielders usually provide a buffer during tough markets.

For 25 years, Steven Halpern, editor of TheStockAdvisors.com, has surveyed the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is one of 100+ ideas in the Best Stocks for 2008 report.

"I like Aflac (NYSE: AFL) as a top conservative choice for 2008," says Chuck Carlson, editor of The DRIP Investor. "The stock is a true 'steady eddy' performer and represents a cornerstone holding for any dividend reinvestment-based portfolio.

"Aflac is the number one provider of "guaranteed-renewable" insurance in the U.S. and the number one insurance company in terms of individual insurance policies in force in Japan. The firm insures more than 40 million people worldwide.

"Aflac's products should see good demand going forward as copays and deductibles are likely to increase for US and Japanese workers over the next several years.

"From a dividend perspective, there's a lot to like. Dividends have increased for 25 consecutive years, and dividend growth has been impressive. Dividends have been increased twice in 2007. With the consensus earnings estimate of $3.80 per share in 2008, look for the firm to give shareholders a generous dividend boost next year.

"Overall, the company offers the stability and consistency investors crave during volatile markets and the stock should handily outperform the market in 2008. Investors should note that Aflac offers a direct-purchase plan whereby any investor may buy shares directly from the company, the first share and every share."

I've just returned from the World Money Show, where some 10,000+ investors gathered to learn about global investing. I had a chance to meet with many of the advisors who were featured at the show, and I am highlighting some of their favorite investment ideas. To view all of the stocks featured in this special global report, click here.

"One of the fastest-growing investment vehicles in the history of the financial markets is the exchange-traded fund," notes Chuck Carlson, editor of The DRIP Investor.

"And the company behind iShares exchange-traded funds is not an American company. It is a United Kingdom-based company. That company is Barclays PLC (NYSE:BCS), which operates in more than 60 countries and manages more than $1 trillion of the world's money.

"ETFs are still very much in their fast-growth phase. While assets have grown sharply, many investors still are not familiar with these investments. That will change over the next few years. With a strong brand and big first-mover advantage, Barclays has positioned itself to be the major beneficiary of this huge expected growth.

"Meanwhile, takeovers are occurring on almost a daily basis. The takeover mania is being fueled by a tidal wave of liquidity. Private equity firms, hedge funds, and corporate America are awash in cash, and they are putting that cash to work by buying firms. And Barclay's is one stock that has reportedly been in the cross-hairs of a buyer.